Colorectal cancer resource library

    Showing 21–39 of 39 results

    Filtered By:
    First FDA-Approved Treatment for HER2-Positive Colorectal Cancer
    Blog

    First FDA-approved treatment for HER2-positive colorectal cancer

    “Historically, patients with HER2-positive metastatic colorectal cancer who have progressed following frontline therapy have had poor outcomes,” said John Strickler, M.D. and lead investigator of the MOUNTAINEER trial. “The FDA approval of a chemotherapy-free combination regimen that specifically targets HER2 is great news for these patients.”

    FDA Approves FRUZAQLA for Previously Treated mCRC
    Blog

    FDA approves FRUZAQLA for previously treated mCRC

    Takeda has announced U.S. Food and Drug Administration (FDA) approval of FRUZAQLA (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

    Blog

    Why the doctors chose robotic-assisted surgery

    In the case of Dr. Paul O'Rourke – a 39-year-old, stage I rectal cancer survivor, and physician at Johns Hopkins – robotic-assisted surgery (RAS) was the surgical option he was fortunate he had.

    Clinical Trial To Evaluate Onvansertib as First-Line mCRC Treatment
    Blog

    Clinical trial to evaluate onvansertib as first-line mCRC treatment

    People with RAS-mutated metastatic colorectal cancer (mCRC) have seen little progress in first-line treatment options over the past two decades, but that could soon change for thousands of new patients, according to a press release from Cardiff Oncology.

    A photograph of Lexie in a chemotherapy chair.
    Blog

    Lexie Haglund: Beating stage IV CRC

    Discover how knowing her G12C biomarker guided Lexie’s stage IV colorectal cancer treatment — from a shock diagnosis to HIPEC surgery — and why screening, research, and self-advocacy matter.

    Blog

    FDA approves new treatment for metastatic CRC with BRAF mutation

    The U.S. Food and Drug Administration has approved encorafenib (marketed as BRAFTOVI) in combination with cetuximab (marketed as ERBITUX) as a second-line therapy for the treatment of adult patients with metastatic colorectal cancer with a BRAFV600E mutation.

    The main corridor at the 2025 ASCO Annual Meeting
    Blog

    2025 ASCO update: Six big studies

    The 2025 ASCO Annual Meeting featured several important studies that could change how colorectal cancer is treated, including a pivotal study for BRAF V600E patients.

    The AllyCon thrive logo.
    Blog

    Watch session videos from AllyCon 2024

    Watch videos of two major general sessions from AllyCon 2024, the Alliance's patient support conference, which took place in Miami Beach in December.

    support group three people

    Get connected with your allies

    There are many ways to find your community through the Alliance. Try one of our online communities.

    Learn More